Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Methotrexate
•
General Rheumatology
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
Related Questions
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
Have you utilized JAK inhibitors in patients on dialysis?
Do you continue TNF inhibitors in patients with a new diagnosis of CLL?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Can lupus anticoagulant be positive despite a normal aPTT?
